Acelyrin, Inc. (SLRN) Research
Acelyrin, Inc. is a biopharmaceutical company focused on discovering, obtaining, and rapidly advancing the development and commercialization of innovative medical therapies. The firm's most advanced experimental drug is izokibep, a potent small protein therapeutic specifically designed to block IL-17A. This compound is currently undergoing Phase 3 clinical evaluations for its use in treating Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis. Additionally, izokibep is being assessed in Phase 2 clinical trials for Axial Spondyloarthritis. Beyond izokibep, Acelyrin is also developing lonigutamab, a humanized immunoglobulin G1 (IgG1) monoclonal antibody that targets the insulin-like growth factor 1 receptor. Lonigutamab is in Phase 1 clinical studies for individuals with thyroid eye disease. Furthermore, the company has SLRN-517, a fully human IgG1 monoclonal antibody aimed at c-KIT, which is in the preclinical stage of development for the treatment of chronic urticaria. Founded in 2020, Acelyrin's corporate headquarters are located in Agoura Hills, California.
Market snapshot
- Symbol
- SLRN
- Price
- $2.27
- Day change
- 0.00%
- Market cap
- $229.2M
- P/E ratio
- -1.70x
- 52-week range
- 1.845-7.25
- Sector
- Healthcare
- Industry
- Biotechnology
- Analyst price target
- $10.50
Peer companies
Recent insider activity
- AyurMaya Capital Management Company, LP — D-Return (9334735 shares) on 2025-05-21
- Kim Mina — A-Award (89526 shares) on 2025-05-21
- Kim Mina — D-Return (190114 shares) on 2025-05-21
- Kim Mina — D-Return (770833 shares) on 2025-05-21
- Kim Mina — D-Return (1195856 shares) on 2025-05-21
Open Acelyrin, Inc. (SLRN) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.